SCHEDULE: Cormorant Asset Management Boosts EyePoint Stake to 9.98%

Cormorant Asset Management, LP and Bihua Chen have disclosed a 9.98% beneficial ownership stake in EyePoint Pharmaceuticals, Inc., holding 8,265,000 shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen, as reporting persons, beneficially own 8,265,000 shares of EyePoint Pharmaceuticals, Inc. Common Stock.
• This ownership represents 9.98% of the issuer's outstanding common stock.
• The percentage is calculated based on 82,787,220 shares outstanding as of October 30, 2025, as reported in EyePoint Pharmaceuticals' Form 10-Q filed on November 6, 2025.
• Cormorant Asset Management, LP serves as the investment manager for Cormorant Global Healthcare Master Fund, LP, which holds these shares.
• Bihua Chen is the managing member of Cormorant Global Healthcare GP, LLC (general partner of the Master Fund) and the general partner of Cormorant Asset Management, LP.
• The shares are held with shared voting power and shared dispositive power for both reporting persons.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and continued investment by a specialized asset manager, suggesting confidence in the company's prospects. The 'ordinary course of business' statement implies a passive, long-term investment rather than an activist stance, which is generally viewed positively by the market.

Positives

• A significant stake by an institutional investor like Cormorant Asset Management can signal confidence in EyePoint Pharmaceuticals' future prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist play.

Negatives

• NA

Risks

• The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest, which is standard but highlights that their interests are primarily financial.
• The concentration of a significant portion of the company's stock in the hands of a single investment manager could lead to increased volatility if the fund decides to significantly alter its position.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by a specialized healthcare investment firm like Cormorant Asset Management in a pharmaceutical company like EyePoint Pharmaceuticals suggests continued investor interest in the biotechnology and pharmaceutical sectors, particularly in companies with potential for growth or specific therapeutic pipelines.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding nearly 10% of the company's stock may instill confidence and potentially attract other investors, positively impacting share price stability and liquidity.
• Management: While the filing states the investment is not for influencing control, a large shareholder can still exert influence through engagement and voting on proposals, potentially aligning management's focus with long-term shareholder value.

Key Dates

Recommendation

The filing indicates a significant, nearly 10% stake by a reputable institutional investor, Cormorant Asset Management, in EyePoint Pharmaceuticals. This suggests a vote of confidence in the company's long-term prospects, as the investment is stated to be in the ordinary course of business and not for control. While this is a positive signal, the filing itself does not provide new operational or financial performance data to warrant a 'buy' recommendation. It primarily confirms a substantial existing investment. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive investor sentiment without implying new fundamental catalysts from this specific disclosure.

Keywords

EyePoint Pharmaceuticals, Cormorant Asset Management, Bihua Chen, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals